A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Further Tests To Determine The Efficacy Of The Drug Nivolumab For Lung Cancer
